Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Yahoo! Finance
On March 12, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that the Phase 3 Enh3ance study of DTX301, an experimental AAV8 gene therapy for the treatment of ornithine transcarbamylase deficiency, yielded favourable findings. Pressmaster/Shutterstock.com DTX301-treated patients showed a statistically significant and clinically meaningful 18% decrease in 24-hour plasma ammonia compared to placebo at Week 36 of the randomised, double-blind, placebo-controlled phase of the trial. Throughout Week 36, the average ammonia AUC0-24 remained within the normal range. Despite appropriate current medication treatment and dietary restriction, eight out of nine patients with abnormal ammonia AUC0-24 at baseline quickly reached normal ammonia levels, which were often maintained during this treatment period. On March 12, JPMorgan reduced its price target on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $120 to $74. The firm maintained an Overweight rating on the shares. JPMorgan
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RAREGlobeNewswire
- Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND [Yahoo! Finance]Yahoo! Finance
- RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law FirmPR Newswire
- Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. InvestorsGlobeNewswire
RARE
Earnings
- 2/12/26 - Miss
RARE
Sec Filings
- 3/30/26 - Form 8-K
- 3/27/26 - Form ARS
- 3/27/26 - Form DEFA14A
- RARE's page on the SEC website